Zanubrutinib plus rituximab demonstrated a clinically meaningful progression-free survival advantage over bendamustine plus rituximab in previously untreated MCL, with a 43% risk reduction for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results